Connect with us

Technology

Invenio Imaging Announces Completion of Enrollment in Landmark Study of AI-Based Image Analysis for Lung Cancer

Published

2 months ago

on

SAN JOSE, Calif., Aug. 3, 2026 /PRNewswire/ — Invenio Imaging, a leader in fresh tissue imaging and artificial intelligence, announced today the completion of patient enrollment in the ON-SITE study, its U.S. pivotal study evaluating NIO® Lung Cancer Reveal, an AI-based image analysis module for the rapid assessment of bronchoscopic lung biopsy specimens imaged with the NIO® Imaging System.

With 1,006 patients enrolled, ON-SITE is one of the largest prospective, multicenter studies conducted in interventional pulmonology. The study collected more than 3,250 fresh biopsy specimens across seven medical centers, with participation from 32 physicians. Specimens were obtained using transbronchial forceps biopsy, cryobiopsy, transbronchial needle aspiration, and endobronchial ultrasound-guided transbronchial needle aspiration.

“Completing enrollment in ON-SITE is a major milestone for Invenio and for our Lung Cancer Reveal program,” said Jay Trautman, PhD, co-founder and CEO of Invenio Imaging. “We are incredibly grateful to the patients, investigators, clinical research teams, participating institutions, and Invenio colleagues who supported this study. Their dedication and collaboration made a clinical effort of this scale possible and have brought us an important step closer to providing rapid, AI-enabled tissue assessment in the bronchoscopy room.”

Despite major advances in bronchoscopy, determining whether a biopsy contains the tissue needed for diagnosis during a procedure remains a significant challenge. Rapid on-site evaluation (ROSE) can provide immediate feedback but requires specialized pathology personnel and is not consistently available.

“As bronchoscopic procedures become more advanced, our ability to assess the tissue collected during the procedure has not generally kept pace,” said Dr. Gustavo Cumbo-Nacheli, interventional pulmonologist in Grand Rapids and a principal investigator for the ON-SITE study. “There is an urgent clinical need for rapid feedback that can help physicians evaluate tissue in the procedure suite. A practical, in-room approach to tissue assessment could have a meaningful impact on bronchoscopy workflows.”

The NIO® Imaging System rapidly images fresh, unprocessed biopsy tissue without traditional freezing, sectioning, or staining, while preserving the specimen for downstream pathology and molecular analysis. NIO® Lung Cancer Reveal applies artificial intelligence to these images to assist physicians in the evaluation of bronchoscopic lung biopsy specimens.

“The scale of ON-SITE is remarkable and reflects an extraordinary collaborative effort across the participating centers,” said Dr. George Cheng, interventional pulmonologist in San Diego and a principal investigator for the ON-SITE study. “Investigators and research teams worked together to enroll patients and collect thousands of specimens across multiple bronchoscopic biopsy techniques. We are proud to have contributed to a prospective study of this scope and importance.”

NIO® Lung Cancer Reveal received FDA Breakthrough Device Designation for its intended use to assist physicians in the evaluation of bronchoscopic lung forceps biopsies. The NIO® Lung Cancer Reveal detects cell/tissue morphology suspicious for cancer in images acquired with the NIO® Imaging System from fresh/unprocessed biopsy specimens. Its output should not be used as the primary diagnosis and physicians should consider all other clinical factors when making a clinical decision. Invenio will analyze the ON-SITE pivotal validation data in support of its regulatory submission. NIO® Lung Cancer Reveal remains investigational in the United States and has not been cleared or approved for clinical use.

About Invenio Imaging Inc.

Invenio Imaging is an emerging, privately held medical device company based in San Jose, California, dedicated to advancing the care of cancer patients by combining fresh tissue imaging and artificial intelligence. The NIO® Imaging System enables rapid imaging of fresh, unprocessed tissue and has been used across a range of surgical and interventional applications.

Invenio Imaging’s first AI product, NIO® Glioma Reveal, is CE-marked and available for clinical use in Europe. NIO® Lung Cancer Reveal, the AI product evaluated in the ON-SITE study, has not been cleared or approved for clinical use in the United States.

Research reported in this press release is supported by the National Cancer Institute of the National Institutes of Health under Award Number 1R44CA281581-01. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

CONTACT: contact@invenio-imaging.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/invenio-imaging-announces-completion-of-enrollment-in-landmark-study-of-ai-based-image-analysis-for-lung-cancer-302840042.html

SOURCE Invenio Imaging

Related Topics:
Continue Reading

Technology

Century Fasteners Corp. Exhibiting at the 2026 International Fastener Expo

Published

2 hours ago

on

September 21, 2026

By

Century Fasteners Corp. and Cherry Aerospace Relationship Showcased at the 2026 International Fastener Expo – October 7th-9th, 2026.

ELMHURST, N.Y., Sept. 21, 2026 //PRNewswire// — Century Fasteners Corp. (www.CenturyFasteners.com) is an authorized distributor for Cherry Aerospace (www.CherryAerospace.com).

Century Fasteners Corp. will exhibit at the 2026 International Fastener Expo (https://fastenershows.com/) in Phoenix, AZ, October 7th–9th, 2026, where Century will showcase its capabilities and relationship with Cherry Aerospace at Booth 2756.

In addition to making world-class Cherry products more broadly available to distributors and OEMs, the partnership expands Century’s existing services to the manufacturing community by enabling the company to provide deeper bill of material coverage to complement its product offering.

About Century Fasteners Corp.

Century Fasteners Corp. is a Master Distributor of fastener and consumable products to the military, aerospace, electronics, industrial, and commercial sectors. Founded in 1955, the AS and ISO certified company stocks more than 100,000 discrete parts, and offers a wide variety of value-added services, including VMI in-plant programs, custom kitting, and supply chain management solutions. Century Fasteners Corp. is an authorized stocking distributor for Cherry Aerospace (www.cherryaerospace.com). Service, Inventory, Integrity™

About Cherry Aerospace

Headquartered in Santa Ana, CA, Cherry Aerospace is a global leader in the design and manufacture of fastening systems for the aerospace industry. The Cherry® name is synonymous with aerospace fasteners, and the CherryMax® line of rivets is the most widely used in the industry. Cherry® Aerospace is well known for their industry leading blind rivets, blind bolts, rivetless nut plates, shear pin fasteners and installation tools. The company is a member of the SPS Fastener Division of Precision Castparts Corp.

For Cherry Aerospace and other product quotes for OEMs or Distributors, email the requirements to Century Fasteners Corp. at sales@centuryfasteners.com. To learn more about the products and services offered by Century Fasteners Corp., visit online at www.CenturyFasteners.com.

Media contact:

John Ringold – Director of Marketing
Century Fasteners Corp
800-221-0769
jringold@centuryfasteners.com
https://www.centuryfasteners.com/

Contact:
***@optonline.net

Photo(s):
https://www.prlog.org/13171987

Press release distributed by PRLog

View original content:https://www.prnewswire.com/news-releases/century-fasteners-corp-exhibiting-at-the-2026-international-fastener-expo-302885273.html

SOURCE Century Fasteners Corp.

Continue Reading

Technology

TMGM and Chelsea Football Club Extend Partnership into Fourth Year, Expanding into the Middle East

Published

2 hours ago

on

September 21, 2026

By

SYDNEY, Sept. 22, 2026 /PRNewswire/ — TMGM and Chelsea Football Club today announced the extension of their partnership into a fourth year, with the collaboration expanding beyond Asia-Pacific into the Middle East.

Since 2023, TMGM has served as Chelsea FC’s Official Online Forex and CFD Trading Partner in Asia-Pacific. The extension advances a partnership spanning matchday visibility, original content and fan engagement.

Three Years of Shared Momentum

In 2026, the partnership reached a milestone when TMGM branding appeared on the back of Chelsea men’s match shirts during the FA Cup – a first in the club’s history. TMGM also joined Chelsea FC’s 2026 Asia-Pacific Pre-Season Tour as an Official Partner, with open training, pitch-side access and post-match tunnel experiences. The tour included a visit by Chelsea players Cole Palmer and João Pedro to TMGM’s Sydney headquarters.

Earlier in 2026, TMGM presented The Famous CFC in Bangkok, where hundreds of supporters attended a live match screening and an exclusive appearance by former Chelsea captain John Terry.

These milestones formed part of a wider programme of premium home-match hospitality, behind-the-scenes visits at Cobham and player-led content under TMGM’s “Trade like a lion” campaign.

A Broader Platform for Year Four

In year four, TMGM’s expanded regional rights will support brand visibility at Chelsea home fixtures, original content featuring players and legends, regional digital campaigns and a China-focused performance series. The programme will also continue through The Famous CFC in selected markets and offer TMGM clients further hospitality and behind-the-scenes access across Chelsea’s matchday, stadium and training environments.

“Over three years, our relationship with Chelsea FC has evolved from regional activations to high-profile moments, including visibility on the club’s FA Cup shirts and its Asia-Pacific tour,” said TMGM. “Entering our fourth year and extending into the Middle East creates opportunities to connect with more audiences through experiences that reflect the ambition of both organisations.”

Chelsea Football Club said: “TMGM has focused on bringing its clients and our supporters closer to the club through digital-first content and in-person events across Asia-Pacific to great effect. We are pleased to extend the partnership into a fourth year and look forward to building on its momentum across the region and also the Middle East.”

About TMGM

Founded in 2013 in Sydney, Australia, TMGM Group is the Official Regional Partner of Chelsea Football Club. As a broker providing global financial product trading, TMGM is regulated by ASIC (Australia), VFSC (Vanuatu), FSC Mauritius, and FSA (Seychelles).

Disclaimer: Investing in leveraged products carries high risks and is not suitable for all investors. You have no interest in the underlying asset. Read the Client Agreement and other disclosure documents set forth on our website. The above information is provided by TMGM Group (Trademax Australia Limited, ABN 76 162 331 311, AFSL 436416, Trademax Global Markets (SE) Limited, FSA licence number SD224, Trademax Global Limited, VFSC 40356 & Trademax Global Markets (International) Pty Ltd, Company No. 195323, Mauritius Investment Dealer Licence No. GB22201012). 

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/tmgm-and-chelsea-football-club-extend-partnership-into-fourth-year-expanding-into-the-middle-east-302884310.html

Continue Reading

Technology

Ridgeway Pharmacy Statement Regarding Website Security Incident Involving Third-Party Vendor

Published

2 hours ago

on

September 21, 2026

By

VICTOR, Mont., Sept. 21, 2026 /PRNewswire/ — Ridgeway Pharmacy, Ltd. (“Ridgeway”) is providing notice of an incident involving its pharmacy website, which was developed by a third-party vendor. Ridgeway identified operational issues on the website and promptly began an investigation with the assistance of external cybersecurity and forensic specialists. That investigation determined that a vulnerability in the vendor-supported website allowed an unknown third party to access the site using elevated privileges, and that certain information may have been accessible as a result. On August 21, 2026, Ridgeway determined that the information potentially involved may have included name, date of birth, address, prescription information, health information, insurance information, and, for a portion of the individuals, payment card information. Importantly, at no time did this incident involve Ridgeway’s internal systems.

Ridgeway takes the privacy and security of information seriously and holds the third parties that support its services to that same standard. Upon learning of this matter, Ridgeway secured and remediated the affected website, stood up a new platform, further restricted access, strengthened monitoring, implemented additional protections against unauthorized activity, and reported the incident to federal law enforcement.

Written notice has been mailed to individuals whose information may have been involved, and out of an abundance of caution Ridgeway is offering complimentary identity protection services through TransUnion, a leading identity protection provider. As a general precaution, individuals are encouraged to review their account statements, health plan explanations of benefits, and credit reports for any unfamiliar activity, to enroll in the complimentary services described in their notification letter, and to report any unusual activity to their financial institution.

Individuals with questions may call Ridgeway’s dedicated toll-free assistance line at 1-833-516-7133, available 8am – 8pm (ET).

View original content:https://www.prnewswire.com/news-releases/ridgeway-pharmacy-statement-regarding-website-security-incident-involving-third-party-vendor-302884264.html

SOURCE Ridgeway Pharmacy

Continue Reading

Trending